MXPA02001562A - Azatioprina topica para el tratamiento de enfermedades orales autoinmunes. - Google Patents

Azatioprina topica para el tratamiento de enfermedades orales autoinmunes.

Info

Publication number
MXPA02001562A
MXPA02001562A MXPA02001562A MXPA02001562A MXPA02001562A MX PA02001562 A MXPA02001562 A MX PA02001562A MX PA02001562 A MXPA02001562 A MX PA02001562A MX PA02001562 A MXPA02001562 A MX PA02001562A MX PA02001562 A MXPA02001562 A MX PA02001562A
Authority
MX
Mexico
Prior art keywords
oral
azathioprine
autoimmune diseases
topical
treatment
Prior art date
Application number
MXPA02001562A
Other languages
English (en)
Inventor
Joel B Epstein
Original Assignee
Oral Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oral Solutions Inc filed Critical Oral Solutions Inc
Publication of MXPA02001562A publication Critical patent/MXPA02001562A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA02001562A 1999-08-13 2000-08-11 Azatioprina topica para el tratamiento de enfermedades orales autoinmunes. MXPA02001562A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14880499P 1999-08-13 1999-08-13
US09/433,418 US7323471B1 (en) 1999-08-13 1999-11-04 Topical azathioprine for the treatment of oral autoimmune diseases
PCT/US2000/021959 WO2001012264A2 (en) 1999-08-13 2000-08-11 Topical azathioprine for the treatment of oral autoimmune diseases

Publications (1)

Publication Number Publication Date
MXPA02001562A true MXPA02001562A (es) 2003-07-21

Family

ID=26846189

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001562A MXPA02001562A (es) 1999-08-13 2000-08-11 Azatioprina topica para el tratamiento de enfermedades orales autoinmunes.

Country Status (12)

Country Link
US (1) US7323471B1 (es)
EP (1) EP1212063B9 (es)
JP (1) JP2003527321A (es)
KR (1) KR20020039332A (es)
AT (1) ATE365555T1 (es)
AU (1) AU6901400A (es)
BR (1) BR0013552A (es)
CA (1) CA2379435C (es)
DE (1) DE60035351T9 (es)
IL (1) IL148133A0 (es)
MX (1) MXPA02001562A (es)
WO (1) WO2001012264A2 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056785A (en) 1960-03-21 1962-10-02 Burroughs Weilcome & Co U S A Purine derivatives
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5310545A (en) 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5691343A (en) 1995-03-30 1997-11-25 Mayo Foundation For Medical Education And Research Use of topical azathioprine to treat inflammatory bowel disorders
US5733915A (en) 1995-03-30 1998-03-31 Glaxo Wellcome Inc. Use of azathioprine to treat crohn's disease
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods

Also Published As

Publication number Publication date
CA2379435A1 (en) 2001-02-22
WO2001012264A2 (en) 2001-02-22
US7323471B1 (en) 2008-01-29
AU6901400A (en) 2001-03-13
EP1212063A4 (en) 2004-02-11
JP2003527321A (ja) 2003-09-16
IL148133A0 (en) 2002-09-12
WO2001012264A3 (en) 2001-10-11
ATE365555T1 (de) 2007-07-15
DE60035351T9 (de) 2008-06-26
EP1212063B9 (en) 2008-04-30
BR0013552A (pt) 2003-07-15
EP1212063A2 (en) 2002-06-12
DE60035351D1 (de) 2007-08-09
DE60035351T2 (de) 2008-02-28
EP1212063B1 (en) 2007-06-27
CA2379435C (en) 2009-05-19
KR20020039332A (ko) 2002-05-25

Similar Documents

Publication Publication Date Title
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
CA2389167A1 (en) Pharmaceutical formulations of resveratrol and methods of use thereof
AP2003002922A0 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
WO2000044367A3 (en) A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
MX249762B (es) Acidos aldonicos de oligosacarido y su uso topico.
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
HUS1300069I1 (hu) Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére
WO2001089554A3 (en) Treatment of acute coronary syndrome with glp-1
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
SE9902597D0 (sv) New use
IL148133A0 (en) Topical azathioprine for the treatment of oral autoimmune diseases
WO2001091856A3 (en) Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
NO20010044D0 (no) Anvendelse av texapyriner i makrofag-medierte sykdommer
WO2001001995A3 (en) Method for treatment of asthma syndrome
WO2001049276A3 (en) Anhydrous gel comprising nsaid for topical administration to the oral cavity
Vena et al. Topical 5-fluorouracil in the treatment of discoid lupus erythematosus. Preliminary study over two years

Legal Events

Date Code Title Description
FG Grant or registration